PMID- 12938144
OWN - NLM
STAT- MEDLINE
DCOM- 20040526
LR  - 20191114
IS  - 0887-8013 (Print)
IS  - 1098-2825 (Electronic)
IS  - 0887-8013 (Linking)
VI  - 17
IP  - 5
DP  - 2003
TI  - Serum cystatin C may predict the early prognostic stages of patients with type 2 
      diabetic nephropathy.
PG  - 164-7
AB  - We determined the relationship between levels of serum cystatin C or serum 
      creatinine (s-Cr) and prognostic stages of type 2 diabetic nephropathy. Serum 
      samples from 174 patients with type 2 diabetes were obtained from Juntendo 
      University Hospital, Tokyo and Juntendo Urayasu Hospital, Chiba, Japan. They were 
      classified into four groups according to the Report of the Ministry of Health and 
      Welfare of Japan as follows: Stage I (normoalbuminuric stage), Stage II 
      (microalbuminuric stage), Stage IIIA (macroalbuminuric stage without renal 
      dysfunction), Stage IIIB (macroalbuminuric stage with renal dysfunction), and 
      Stage IV (renal failure stage). Among these patients, 68 were Stage I, 29 Stage 
      II, 32 Stage IIIA, 17 Stage IIIB, and 28 Stage IV. The levels of serum cystatin C 
      were measured using the Dade Behring Cystatin C assay with automated Dade Behring 
      Nephelometer II (BNII) (Dade Behring Marburg GmbH, Germany). The mean levels of 
      serum cystatin C in Stage IIIA were significantly higher than those in Stage I or 
      II (P<0.00001, P<0.0005, respectively). The mean levels of serum cystatin C in 
      Stage IIIB and Stage IV were also significantly higher than those in Stage I 
      (P<0.00001). However, the mean levels of serum creatinine (s-Cr) in Stage IIIA 
      were not significantly higher than those in Stage I or II. The levels of s-Cr in 
      Stage IIIB and Stage IV were significantly higher than those in Stage I 
      (P<0.00001). Receiver operating characteristic (ROC) plots demonstrated that the 
      area under the curve (AUC) of cystatin C (0.76) was greater than that of s-Cr 
      (0.66). As an early prognostic marker of type 2 diabetic nephropathy, serum 
      cystatin C was better than s-Cr in terms of sensitivity and specificity. It 
      appears that the levels of serum cystatin C may predict early prognostic stages 
      of patients with type 2 diabetic nephropathy.
CI  - Copyright 2003 Wiley-Liss, Inc.
FAU - Shimizu, Ayumi
AU  - Shimizu A
AD  - Division of Nephrology, Department of Internal Medicine, Juntendo University 
      School of Medicine, Tokyo, Japan.
FAU - Horikoshi, Satoshi
AU  - Horikoshi S
FAU - Rinnno, Hisaki
AU  - Rinnno H
FAU - Kobata, Mami
AU  - Kobata M
FAU - Saito, Kensuke
AU  - Saito K
FAU - Tomino, Yasuhiko
AU  - Tomino Y
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Clin Lab Anal
JT  - Journal of clinical laboratory analysis
JID - 8801384
RN  - 0 (Biomarkers)
RN  - 0 (CST3 protein, human)
RN  - 0 (Cystatin C)
RN  - 0 (Cystatins)
RN  - AYI8EX34EU (Creatinine)
SB  - IM
CIN - J Clin Lab Anal. 2004;18(1):55-60. PMID: 14730560
MH  - Biomarkers/blood
MH  - Creatinine/blood
MH  - Cystatin C
MH  - Cystatins/*blood
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Diabetic Nephropathies/blood/etiology/*pathology
MH  - Humans
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - ROC Curve
MH  - Sensitivity and Specificity
MH  - Severity of Illness Index
PMC - PMC6807816
EDAT- 2003/08/26 05:00
MHDA- 2004/05/27 05:00
PMCR- 2003/08/18
CRDT- 2003/08/26 05:00
PHST- 2003/08/26 05:00 [pubmed]
PHST- 2004/05/27 05:00 [medline]
PHST- 2003/08/26 05:00 [entrez]
PHST- 2003/08/18 00:00 [pmc-release]
AID - JCLA10087 [pii]
AID - 10.1002/jcla.10087 [doi]
PST - ppublish
SO  - J Clin Lab Anal. 2003;17(5):164-7. doi: 10.1002/jcla.10087.